Metropolis Healthcare , a leading diagnostic services provider, has reaffirmed its commitment to organic business growth and provided updates on its recent acquisition during a conference call. The company has set a target of 70-100 basis points (bps) for organic business growth in the fiscal year 2026 (FY26) and expects volume growth of 10-11% for the year.

Core Diagnostics Integration Progress

Metropolis Healthcare is making progress with the integration of Core Diagnostics, which it acquired for Rs 247 crore. The company has outlined an ambitious plan for improving Core Diagnostics' profitability:

• Breakeven expected in Q4FY25
• Low single-digit margins projected for Q1FY26
• High single-digit margins anticipated in Q2FY26
• Double-digit margins targeted by the end of FY26

Managing Director Surendran Chemmenkotil stated that Core Diagnostics' margins should align with Metropolis' overall margins within three years of acquisition. This acquisition was strategically aimed at strengthening the company's cancer diagnostics portfolio and expanding its presence in Northern and Eastern India.

Recent Financial Performance

Metropolis reported strong quarterly results:

The company's TruHealth segment is showing 20% growth, indicating positive momentum in this area.

Growth Strategy and Outlook

The confirmation of the organic business growth target highlights Metropolis Healthcare's focus on expanding its core diagnostic services. The 10-11% volume growth expectation for the year indicates a strong outlook for service demand, supporting the company's multi-faceted approach to expansion in the diagnostic services market.

Upcoming Earnings Call

Metropolis Healthcare has scheduled its earnings conference call for the quarter and half-year ended September 30, 2025, on November 6, 2025. The call timing has been revised to 10:30 AM (IST) from the previously announced 10:00 AM.

Management Participation

Key management personnel participating in the earnings call will include:

• Ms. Ameera Shah, Chairperson & Whole-Time Director
• Mr. Surendran Chemmenkotil, Managing Director
• Mr. Sameer Patel, Chief Financial Officer
• Mr. Avadhut Joshi, Chief Business Development Officer

Investor Implications

For investors and market analysts, Metropolis Healthcare's reaffirmation of its organic growth target, volume growth expectations, and the progress update on Core Diagnostics integration provides clear benchmarks for evaluating the company's performance. The targeted growth range for organic business, combined with the volume growth expectation and the strategic acquisition, suggests that the company is pursuing a robust expansion strategy.

As the diagnostic services sector continues to evolve, Metropolis Healthcare's growth targets and strategies will be closely watched by industry observers and stakeholders alike. Investors and interested parties are encouraged to participate in the upcoming earnings call for a more comprehensive understanding of Metropolis Healthcare's financial position and future outlook.

Metropolis Healthcare , a leading diagnostic services provider, has reported a robust financial performance for the second quarter of the fiscal year 2025-26, with significant growth in both revenue and profitability.

Financial Highlights

The company's consolidated revenue for Q2 rose to ₹4,291.91 million, marking a 22.7% increase from ₹3,497.89 million in the same quarter last year. The consolidated net profit for Q2 increased to ₹528.90 million, up 13.3% from ₹466.98 million in the corresponding period of the previous year.

For the half-year ended September 30, 2025, Metropolis Healthcare reported consolidated revenue of ₹8,152.55 million, compared to ₹6,631.44 million in the prior year. The consolidated profit for this six-month period stood at ₹981.38 million, against ₹848.08 million in the previous year.

Interim Dividend Declaration

The Board of Directors of Metropolis Healthcare has declared an interim dividend of ₹4 per equity share of face value ₹2 each for the financial year 2025-26. The record date for the purpose of this interim dividend payment has been set as November 11, 2025.

Business Acquisitions

Metropolis Healthcare has completed several strategic acquisitions during the period:

1. DAPIC Metropolis Healthcare Private Limited in May 2025 for a purchase consideration of ₹346.1 million.
2. Scientific Metropolis Pathology Private Limited in June 2025 for ₹720 million.
3. Dr. R.S. Patil's Ambika Pathology Laboratory in September 2025 for ₹170 million.

Operational Performance

The significant growth in both revenue and profitability underscores Metropolis Healthcare's strong operational performance and market position in the diagnostic services sector. The company's ability to increase its top line by nearly 23% while improving its bottom line by 13.3% demonstrates effective cost management and operational efficiency.

Looking Ahead

As Metropolis Healthcare continues to demonstrate strong financial performance and strategic acquisitions, the company's ability to capitalize on the growing demand for diagnostic services while managing costs effectively and integrating new acquisitions will be crucial for its future success.

Metropolis Healthcare's Q2 results reflect a company on a solid growth path, with improvements across key financial metrics. The declaration of an interim dividend further underscores the company's financial health and its commitment to delivering value to shareholders.